Physician profile
Robert Goldberg
NPI 1780628362
$5,587.89
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,545 · 2020: $43.29.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dova Pharmaceuticals | $3,015.02 | 2019 | |
| Tosoh Bioscience, INC. | $427.00 | 2019 | |
| Amgen INC. | $240.29 | 2019 | |
| Genentech USA, INC. | $236.24 | 2019-2020 | |
| Janssen Biotech, INC. | $189.54 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $125.28 | 2019 | |
| Genzyme Corporation | $118.92 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $109.73 | 2019 | |
| Lilly USA, LLC | $98.24 | 2019 | |
| Janssen Pharmaceuticals, INC | $88.09 | 2019 | |
| Pfizer INC. | $79.82 | 2019 | |
| Seagen INC. | $71.94 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $67.43 | 2019 | |
| Incyte Corporation | $65.05 | 2019 | |
| Merck Sharp & Dohme LLC | $64.45 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.98 | 2019 | |
| Eisai INC. | $56.87 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $49.78 | 2019 | |
| Celgene Corporation | $49.29 | 2019 | |
| Verastem, INC. | $45.52 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $40.62 | 2019 | |
| Kyowa Kirin, INC. | $38.98 | 2019 | |
| Taiho Oncology, INC. | $36.95 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.85 | 2019 | |
| Gilead Sciences, INC. | $32.40 | 2019 | |
| Allergan, INC. | $30.78 | 2019 | |
| Emd Serono, INC. | $26.48 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $25.50 | 2019 | |
| Bio Products Laboratory USA, INC. | $17.13 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $16.09 | 2020 | |
| Rigel Pharmaceuticals, INC. | $15.36 | 2019 | |
| Tesaro, INC. | $13.27 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Goldberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.